Loading clinical trials...

LIFUS For Neurological Disorders | Clinical Trials | Clareo Health

RECRUITINGNA

LIFUS For Neurological Disorders

Clinical Effects of Low-Intensity Focused Ultrasound Neuromodulation in Patients With Neurological and Psychiatric Disorders

NCT07417280•University Health Network, Toronto

View on ClinicalTrials.gov

Summary

Low intensity focused ultrasound (LIFUS) has the potential to be used as a means of non-invasive neuro-modulation. To this day, the use of LIFUS is under investigation. Studies in healthy subjects have shown that application of LIFUS to the motor region of the brain can mildly decrease neuron excitability in healthy controls. The purpose of the present study is to evaluate the effects of LIFUS on brain tissue excitability in patients with movement disorders in order to elucidate the therapeutic potential of LIFUS.

Eligibility

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•18-85 years of age
•Patients diagnosed with neurological disorders, (such as epilepsy, brain tumour, movement disorders) or psychiatric disorders (such as substance abuse disorder)
•Patients undergoing medical or surgical treatment (such as DBS) for neurological disorders

Exclusion Criteria

•History of stroke
•Comorbid dementia
•Scored below 22 on the Montreal Cognitive Assessment (MoCA)
•Has an implanted cardiac pacemaker or implantable cardioverter-defibrillator (ICD)
•Presence of metal implanted in body that is contraindicated in TMS/MRI
•Pregnancy
•Major depression/psychiatric disorder that in the opinion of the Investigator will affect patient's understanding of study procedures and willingness to abide by all procedures during the course of the study
•Receiving a psychotropic medication or taking recreational substances that in the opinion of the investigator will significantly affect safety of the protocol
•Major systemic illness or infection

Locations (1)

Toronto Western Hospital, 399 Bathurst St

Toronto, Ontario, Canada

Key Dates

Start Date

December 2, 2025

Primary Completion Date

December 31, 2035

Completion Date

December 31, 2040

Last Updated

February 18, 2026

Enrollment

ESTIMATED participants

Conditions

Parkinson's Disease (PD)Essential TremorOrthostatic TremorDystoniaEpilepsySubstance Abuse DisorderDeep Brain Stimulation

Interventions

LIFUS

DEVICE

Sham LIFUS

DEVICE

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

NCT07310264

Healthy Volunteers (HV)Parkinson's Disease (PD)

View study

RECRUITINGNA

Dual Lead Thalamic Deep Brain Recording (DBR)-DBS Interface for Closed Loop Control of Severe Essential Tremor

NCT04212780

Essential Tremor

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 18, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

LIFUS For Neurological Disorders

Inclusion Criteria

Exclusion Criteria

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

Dual Lead Thalamic Deep Brain Recording (DBR)-DBS Interface for Closed Loop Control of Severe Essential Tremor

Algorithms for Programming DBS Systems for ET

Deep Brain Stimulation Surgery for Movement Disorders

Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease

Stimulating Specific Brain Areas (VOP/VIM) With Electricity to Improve Movement and Muscle Control